logo
Plus   Neg
Share
Email

Roche's Tecentriq Gets 2 EU Approvals To Treat Adults With NSCLC, ES-SCLC

Swiss drug major Roche Group (RHHBY) announced Friday two approvals from European Commission for Tecentriq (atezolizumab) to treat adults with non-squamous non-small cell lung cancer or NSCLC, the most common form of advanced lung cancer, and extensive-stage small cell lung cancer or ES-SCLC, respectively.

In a statement, the company announced that the European Commission or EU has approved and granted marketing authorisation for Tecentriq in combination with chemotherapy (carboplatin and Abraxane), for the initial treatment of adults with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.

This approval is based on results from the Phase III IMpower130 study, which demonstrated that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone in the intention-to-treat wild-type or ITT-WT population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone.

Separately, EU approved Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer or ES-SCLC. Roche noted that this combination is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of ES-SCLC. The combination significantly improved overall survival and progression-free survival for the first time in over 20 years.

This approval is based on results from the Phase III IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared with chemotherapy alone in the intention-to-treat or ITT population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone.

At present, Roche has nine Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines across different types of lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Kylie Cosmetics and Kylie Skin is set for a growth after the cosmetics company launched by Kylie Jenner in 2015 sold a major majority stake to beauty conglomerate Coty for $600 million. Jenner, who has been maintaining the full ownership of the company since its launch, sold 51 percent stake in Kylie... FedEx Corp. Chairman and CEO Fred Smith issued a challenge to the New York Times for publishing a "distorted and factually incorrect" story regarding corporate tax payments by the package delivery giant. The New York Times reported on Sunday that FedEx had made a major push for a reduction in corporate taxes when Donald Trump won the presidential election. A new study showed that foot traffic at Starbucks stores declined after the coffee giant changed to an 'open bathroom' policy. According to the study, store attendance per month at Starbuck stores declined 6.8 percent, relative to nearby restaurants and cafes, after the company made changes to its bathroom policy. In May 2018, Starbucks announced a new bathroom policy.
Follow RTT
>